ADC Therapeutics SA

NYSE:ADCTUnited States

ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom.

Contact Information

Headquarters

Biopole, route de la Corniche 3BEPALINGES, Switzerland 1066

Phone

---

Fax

---

Executives

Non-Executive Chairman of the Board

Ron Squarer

Chief Executive Officer, Director

Ameet Mallik

Chief Financial Officer

Jose Carmona

Chief Scientific Officer

Patrick Van Berkel

Chief Legal Officer

Peter Graham